Ironwood Pharmaceuticals Overview
- Founded
-
1998
- Status
-
Public
- Employees
-
219
- Stock Symbol
-
IRWD
- Share Price
-
$12.01
- (As of Tuesday Closing)
Ironwood Pharmaceuticals General Information
Description
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Primary Office
- 100 Summer Street
- Suite 2300
- Boston, MA 02110
- United States
+1 (617) 000-0000
Ironwood Pharmaceuticals Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.01 | $11.91 | $10.13 - $14.21 | $1.82B | 153M | 3.43M | $1.08 |
Ironwood Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 1,717,142 | 1,804,020 | 1,964,369 | 2,383,287 |
| Revenue | 415,637 | 413,753 | 389,523 | 428,413 |
| EBITDA | 236,101 | 232,604 | 140,399 | 98,263 |
| Net Income | 173,100 | 528,448 | 106,176 | 21,505 |
| Total Assets | 975,690 | 1,126,927 | 559,238 | 402,748 |
| Total Debt | 416,084 | 475,802 | 453,702 | 431,222 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ironwood Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ironwood Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Ironwood Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segmen
Pharmaceuticals
Boston, MA
219
As of 2021
00000
000000000
00000
000000
s nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000000000000
San Francisco, CA
00
As of 0000
000.00
000
0000-00-00
00000000000
000.00
000000
t, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000 000000000
Cambridge, MA
0000
As of 0000
00.000
0000
00.000
Add Comparison
Ironwood Pharmaceuticals Competitors (31)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| OrphoMed | Venture Capital-Backed | San Francisco, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
| 0000000 000000000 | Formerly VC-backed | Tel Aviv, Israel | 000 | 00000 | 000000000 | 00000 |
| 000000000 00000000 | Private Equity-Backed | San Diego, CA | 000 | 00000 | 0000000 0000 | 00000 |
| 0000000000 0000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000&0 |
Ironwood Pharmaceuticals Patents
Ironwood Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210261690-A9 | Method of generating anti-linaclotide antibodies and uses thereof | Abandoned | 11-May-2018 | 000000000 | |
| AU-2018302255-A1 | Efficacy of a gastro-retentive bile acid sequestrant dosage form | Pending | 19-Jul-2017 | 0000000000 | |
| US-20200138854-A1 | Method of detecting and quantifying bile acid from saliva | Abandoned | 19-Jul-2017 | 0000000000 | |
| CA-3070082-A1 | Efficacy of a gastro-retentive bile acid sequestrant dosage form | Pending | 19-Jul-2017 | 0000000000 | |
| EP-3654953-A4 | Efficacy of a gastro-retentive bile acid sequestrant dosage form | Pending | 19-Jul-2017 | A61K31/785 |
Ironwood Pharmaceuticals Executive Team (30)
Ironwood Pharmaceuticals Board Members (23)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alexander Denner Ph.D | Self | Board Member | 000 0000 |
| Andrew Dreyfus | Self | Board Member | 000 0000 |
| Benjamin Cravatt Ph.D | Self | Board Member, Advisory Team | 000 0000 |
| Catherine Moukheibir | Self | Board Member | 000 0000 |
| Edward Owens | Self | Board Member | 000 0000 |
Ironwood Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Ironwood Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|